This $591,842 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to evaluate the in vivo efficacy and clinical translatability of a novel therapeutic approach for treating liver fibrosis. The key objectives are: 1) establishing the in vivo efficacy of the VSR-H5 therapeutic in a mouse model of carbon tetrachloride-induced liver fibrosis, and 2) confirming the presence of the target epitope in human cirrhotic liver tissue and evaluating VSR-H5's ability to reverse fibrotic cellular phenotypes in primary human liver stellate cells. Successful completion of this Phase I STTR project is expected to provide the necessary data to justify further investment in this strategy for treating liver fibrosis, a progressive condition that currently lacks FDA-approved drug therapies.
Generated 1/28/25, 10:44 AM